[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462687":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":30,"locations":38,"responsibleParty":52,"collaborators":30,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":30,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":30,"overallStatus":74,"whyStopped":30,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"H. Lundbeck A\u002FS","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Lu AG09222 Low Dose","EXPERIMENTAL","Participants will receive a single dose of Lu AG09222 by subcutaneous (SC) injection on Day 1.",[13],"Drug: Lu AG09222",{"label":15,"type":10,"description":16,"interventionNames":17},"Lu AG09222 High Dose","Participants will receive a single dose of Lu AG09222 by SC injection on Day 1.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Participants will receive a single dose of placebo matching LU AG0922 by SC injection on Day 1.",[23],"Drug: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Lu AG09222","Lu AG09222 will be administered per schedule specified in the arm description.",[15,9],null,{"type":26,"name":19,"description":32,"armGroupLabels":33,"otherNames":30},"Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.",[19],[35],{"name":36,"affiliation":5,"role":37},"Email contact via H. Lundbeck A\u002FS","STUDY_DIRECTOR",[39],{"facility":40,"status":30,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":30},"PAREXEL International","Glendale","California","91206","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-118.25508,34.14251,{"lat":50,"lon":49},{"type":53,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100462687","phase-1-a-study-investigating-the-movement-of-lu-ag09222-into-through-and-out-of-the-body-of-healthy-caucasian-chinese-and-japanese-participants-100462687",false,"NCT05304910","A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants","Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Study Investigating the Safety, Tolerability and Pharmacokinetic Properties of Lu AG09222 in Healthy Caucasian, Chinese and Japanese Subjects","Inclusion Criteria:\n\n* The participant is Japanese, defined as having 4 Japanese grandparents, or the participant is Caucasian, or the participant is Chinese, defined as having 4 Chinese grandparents.\n* The participant has a body mass index (BMI) ≥18 and ≤28 kilograms (kg)\u002Fsquare meter (m\\^2) at the Screening Visit and at the Baseline Visit.\n\nExclusion Criteria:\n\n* The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.\n* The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for \\>5 years prior to the first dose of investigational medicinal product (IMP).\n* The participant has had major surgery (excluding laparoscopic cholecystectomy or uncomplicated appendectomy) \\\u003C6 months prior to the first dose of IMP.\n* The participant has previously been dosed with Lu AG09222.\n* The participant has a history of severe drug allergy or hypersensitivity.\n\nOther inclusion and exclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":66,"type":67},52,"ACTUAL","INTERVENTIONAL",[70],"PHASE1","The main goal of the study is to learn more about how the body absorbs and eliminates Lu AG09222 after a single dose is injected under the skin. Researchers will also investigate safety and tolerability effects of Lu AG09222 after administration.",[73],"Migraine","COMPLETED","2022-11-08",{"date":77,"type":67},"2022-11-10",{"date":79,"type":67},"2022-03-18",{"date":81,"type":67},"2022-10-30",{"name":5,"class":6},1]